- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab 2018;20:5–21.
- Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes 2019;12:1973–85.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3–14.
Perspectives
How does this study impact clinical practice?
- A dose-dependent superiority on glycaemic efficacy and body weight reduction was evident with tirzepatide versus placebo, GLP-1RA, and basal insulin.
- Tirzepatide did not increase the odds of hypoglycaemia but was associated with increased gastrointestinal adverse events.
- These results will help clinicians to determine the optimal place for tirzepatide among existing treatment option for T2D.
